CSI Market
Sign In | Register

Protagenic Therapeutics Inc new (PTIX) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access PTIX quarterly Cash Flow →
This cash flow overview for Protagenic Therapeutics Inc new spans from Dec 31 2021 to Mar 31 2026, illustrating how cash generation and usage have shifted across recent reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Mar 31 2026)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income1.37
Depreciation & amortization0.05
Amortization of Other Assets1.57
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Goodwill, Impairment Loss0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.42
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants-2.63
Debtor Reorganization Items Gain Loss On Settlement Of Other Claims Net-
Interest Expense-
Legal Fees Incurred Through Issuance Of Preferred Stock-
Derivative Gain Loss On Derivative Net-
Realized Gain Loss On Sale Of Marketable Securities-0.05
Gain On Settlement Of Accounts Payable And Accrued Liabilities-0.08
Adjustment Increase In Note Payable For Acquisition Of Phytanix Bio-0.10
Increase Decrease In Value Added Tax Receivable-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Other Receivables0.00
Increase (Decrease) in Accounts Payable1.04
Increase (Decrease) in Accrued Liabilities0.02
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense-0.05
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-4.59
Discontinued operations0.00
Net Cash flow from Operating Activities-2.81
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities0.00
Payments to Acquire Marketable Securities0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments for (Proceeds from) Previous Acquisition0.94
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net-0.31
Discontinued operations0.00
Net Cash Flow from Investing Activities0.63
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.06
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock4.35
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock4.30
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-4.83
Proceeds From Bridge Loans-
Warrants Issued For Placement Agent-
Warrants Issued For Settlement And Conversion Of Debt-
Settlement Of Debt By Issuance Of Series B Preferred Stock-
Reclassification Of Warrants To Derivative Liabilities From Equity-
Accrued Liabilities Paid Through Issuance Of Preferred Stock-
Proceeds From Pik Convertible Debt-
Debt Discount From Issuance Costs On Convertible Notes-
Issuance Of Shares And Warrants From Offering-
Proceeds From Notes Payablerelatedparty-
Debt Discount From Issuance Costs Paid On Pik Convertible Notes-
Proceeds From Notes Payable Related Party-
Issuance Of Shares And Warrants From Offering Net Of Offering Cost-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities3.87
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-2.81
Total Cash Flow1.70
4 historic quarters locked

Sign in to unlock the full Protagenic Therapeutics Inc new cash flow history.

Sign In Create Free Account

About Protagenic Therapeutics Inc New Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20260331)
  • Filed with the SEC: August 14, 2026
  • Source: form10-k.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001493152-26-038255

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License